Regarding GLP-1 medications, which statement is true about obesity?

• A. They are approved for obesity in all regions
• B. They are approved for obesity in adults only
• C. They are not approved for any metabolic conditions
• D. They are approved for T2DM but not for obesity

Answer: (D)

GLP-1 receptor agonists help with weight and glucose control by mimicking the incretin hormone GLP-1. Because of this, many of these medications are approved to treat obesity in adults, and in several regions they’re also approved for weight management in certain pediatric age groups. At the same time, these drugs are well established for treating type 2 diabetes, which is why their use in metabolic care often spans both obesity and diabetes management. But approvals aren’t uniform worldwide; some countries allow obesity indications for adults only, others extend to certain adolescents, and some regions may not grant obesity labeling at all.

So the takeaway is that GLP-1 medications can be approved for obesity in many contexts and are also approved for T2DM, with the exact indications depending on regional regulatory decisions and patient age.